News
Date:
Dear Members of the CRS Community,
I am excited to be one of the first members of the recently established Nanomedicine and Nanoscale Drug Delivery Focus Group from the Controlled Release Society! This initiative is a fantastic opportunity to further pursue the goals of the Society and increase…
Date:
Dear Controlled Release Society Members,
I am writing today to tell you how excited I am to be one of the first members of the Oral Delivery Focus Group of the Controlled Release Society. The Oral Delivery Focus group is one of five new focus groups being made available to our scientific community…
Date:
Luminary Maria Jose Alonso, PhD
Professor of Pharmaceutical Technology
University of Santiago de Compostela, Spain
1. What sparked your interest in science in general and drug delivery in particular?
Since I was a teenager, I was interested in chemistry, and wondered how chemical compounds…
Date:
PRNewswire: August 24, 2017 – BOONTON, NJ, U.S.A. – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, announced today that the first woman has been dosed in its phase 2a clinical trial to evaluate Ovarest™, an…
Date:
PRNewswire: August 24, 2017 – WILSON, WY, U.S.A. – SynAgile Corporation (www.synagile.com), a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse™ technology platform, today announced the closing of a $10.4 million round of…
Date:
PRNewswire: August 23, 2017 – RALEIGH, NC, U.S.A. – BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today that at the end of 2017, Dr. Mark A. Sirgo will retire as BDSI’s president and chief executive officer, roles which he has held since 2005. Dr. Sirgo will remain as vice…
